IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

IceCure Medical (ICCM) added Legacy Health in Portland, OR, as a new U.S. clinical site for its ChoICE Study, evaluating ProSense® cryoablation for low-risk breast cancer. The study, approved by the FDA, aims to enroll 400 patients across 30 sites. Dr. Nathalie Johnson will lead the site's participation. IceCure's ProSense® is the only FDA-cleared device for this treatment in specific patients.

Original reporting
Published Oct 6, 2026, 12:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site — source image
Decision brief

The 30-second read

$ICCMBullishLow
01

Why it matters

Adding a new site increases patient enrollment capacity, supporting data collection for future regulatory or reimbursement submissions.

02

Market read

The announcement is a modest, positive catalyst for IceCure, but unlikely to drive significant short‑term price movement.

03

What to watch

Potential regulatory or reimbursement hurdles could limit commercial uptake despite broader enrollment.

Relevance 6/10Novelty 7/10Timing: today

Background

IceCure Medical develops cryoablation devices; the ChoICE Study is a post‑market FDA‑approved trial to gather real‑world data on its ProSense® system for low‑risk breast cancer.

Company-level read

Ticker impact

$ICCMBullishMedium confidence
Context

IceCure Medical announced the addition of Legacy Health in Portland as a new U.S. clinical site for its post‑marketing ChoICE Study on ProSense® cryoablation for low‑risk breast cancer.

Expected impact

likely modest upside as investors price in broader trial enrollment and data generation

Evidence & confidence

Clinical‑trial expansion is a positive catalyst but the immediate market impact is limited; the news is new but scale is modest.

Market effects

May reinforce confidence in minimally invasive cryoablation technologies within the med‑tech sector.

Limited to U.S. biotech/med‑tech investors; no broad regional effect.

Minimal global impact; primarily relevant to IceCure shareholders.

Counterpoint

The trial expansion may not translate into commercial revenue if later-phase data are inconclusive.

Key entities

  • IceCure Medical Ltd.

    Developer of the ProSense® cryoablation system, ticker ICCM.

  • Legacy Health

    Non‑profit health system in Oregon adding a clinical site for the ChoICE Study.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.